Jessica Shiu
Dermatology · Irvine, CANPI 1134514888
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. TELA Bio, Inc. accounts for 80.6% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for dermatology clinicians in CA, where the typical reported total is $1,655.
Across 2 payments — averaging $49.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TELA Bio, Inc.$80
- Teva Pharmaceuticals USA, Inc.$19
Across 21 payments — averaging $4792.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$101K
What the payments were for
- Food & beverage$99100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TELA Bio, Inc. | 1 | $80 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
How this compares
$99 in reported general payments places this provider in the 10th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 44 | $160,742 |
| Dupixent SyringeDupilumab | 11 | $38,128 |
| Clobetasol Propionate | 56 | $5,488 |
| Tacrolimus | 15 | $2,927 |
| Ketoconazole | 159 | $2,215 |
| Clindamycin Phosphate | 43 | $998 |
| Fluocinonide | 29 | $984 |
| Doxycycline Monohydrate | 22 | $706 |
| Triamcinolone Acetonide | 47 | $533 |
| Gabapentin | 17 | $318 |
| Hydrocortisone | 17 | $236 |
| Ciclopirox | 13 | $185 |
| Mupirocin | 13 | $154 |
| MethotrexateMethotrexate Sodium | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Irvine
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.